New York, Jan 11, 2026, 08:22 EST — Market closed.
- Shares of Regencell Bioscience closed Friday 10.6% higher at $45.79, bouncing back sharply after a volatile session.
- The stock swung from $35.13 up to $50.92, with roughly 1.56 million shares changing hands.
- Traders enter Monday with eyes on any developments linked to a DOJ subpoena and funding concerns highlighted in the company’s most recent annual report.
Regencell Bioscience Holdings Ltd shares closed Friday up 10.6% at $45.79, recovering sharply after dipping roughly 15% during the session. The Nasdaq-listed stock kicked off the day at $36.08 and swung between a low of $35.13 and a high of $50.92.
U.S. markets were closed Sunday, leaving Monday to reveal if buyers will step back in as trading volume picks up—or if this rally will vanish just as fast as it appeared.
The stock’s volatility unfolds amid legal and financial alarms. In its annual report filed Oct. 31, Regencell revealed it received a subpoena and correspondence from the U.S. Department of Justice concerning trading in its ordinary shares, as well as other operational, financial, and accounting issues. The company warned it anticipates hefty legal expenses and potential fines or penalties. The filing also noted the auditor expressed “substantial doubt” about Regencell’s ability to continue as a going concern, citing “extreme price and volume fluctuations” in the shares. (SEC)
A “going concern” note is accounting jargon indicating that auditors believe the company might lack sufficient resources to continue operating through the next year without securing additional funds.
Regencell describes itself as an early-stage bioscience firm focused on traditional Chinese medicine (TCM) therapies targeting neurocognitive conditions like ADHD and autism spectrum disorder, alongside infectious diseases including COVID-19. (Regencell Bioscience –)
The company’s investor relations page hasn’t posted anything new since Oct. 31, the day it announced filing its annual report. That means recent price moves aren’t backed by any fresh corporate news. (Regencell Bioscience –)
The spotlight shifts to trading mechanics now: volume, opening gaps, and any fresh regulatory filings. Nasdaq’s earnings page for the stock reveals no scheduled earnings report date from its data provider. (Nasdaq)
The downside is straightforward. Should the federal probe expand, legal costs spike beyond forecasts, or if the company seeks financing that dilutes shareholders, a stock already volatile on a typical day could plunge sharply.
